US8809264B2

Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors

Claim Score by NHIP

Read claim 9, the broadest

Abstract

The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

US8809264B2, drawing sheet 1
Sheet 1 of 834

Term

Projected expiry 2 March 2029.

  1. Priority
  2. Filed
  3. Granted
  4. Today
  5. Projected expiry

15 claims: 5 independent, 10 dependent

  1. 1
    A compound of Formula I:as well as the pharmaceutically acceptable salts thereof, wherein: A is selected from H, —(C═O)—O—R 1 , —(C═O)—R 2 , —C(═O)—NH—R 2 , or —S(O) 2 —R 1 , —S(O) 2 NHR 2 ;each R 1 is independently selected from the group consisting of: (i) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(ii) heterocycloalkyl or substituted heterocycloalkyl;(iii) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;each R 2 is independently selected from the group consisting of: (i) hydrogen;(ii) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(iii) heterocycloalkyl or substituted heterocycloalkyl;(iv) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;G is selected from-NHS(O) 2 —R 3 ;where each R 3 is independently selected from: (i) heterocycloalkyl or substituted heterocycloalkyl;and (ii) C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;L is selected from —CH 2 —, —O—, —S—, or —S(O) 2 —;X and Y taken together with the carbon atoms to which they are attached to form a cyclic moiety selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;W is absent;Z is selected from the groups consisting of: (vi) aryl, substituted aryl;(vii) heteroaryl, substituted heteroaryl;(viii) —C 3 -C 12 cycloalkyl, substituted —C 3 -C 12 cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl;(ix) —C 1 -C 6 alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;(x) —C 2 -C 6 alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;(xi) —C 2 -C 6 alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;j=0, 1, 2, 3, or 4;k=1, 2, or 3;m=0, 1, or 2;and denotes a carbon-carbon single or double bond.
  2. 2
    A compound of Formula II:as well as the pharmaceutically acceptable salts thereof, wherein each of X 1 , X 2 , X 3 and X 4 are independently selected from —CR 6 and N, wherein R 6 is independently selected from: (i) hydrogen;halogen;—NO 2 ;—CN;(ii) -M-R 4 , M is O, S, NH, where R 4 is as previously defined;(iii) NR 4 R 5 , where R 4 and R 5 are as previously defined;(iv) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;(v) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(vi) heterocycloalkyl or substituted heterocycloalkyl;A is selected from H, —(C═O)—O—R 1 , —(C═O)—R 2 , —C(═O)—NH—R 2 , or —S(O) 2 —R 1 , —S(O) 2 NHR 2 ;each R 1 is independently selected from the group consisting of: (i) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(ii) heterocycloalkyl or substituted heterocycloalkyl;(iii) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;each R 2 is independently selected from the group consisting of: (i) hydrogen;(ii) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(iii) heterocycloalkyl or substituted heterocycloalkyl;(iv) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;G is selected from —NHS(O) 2 —R 3 ;where each R 3 is independently selected from: (i) heterocycloalkyl or substituted heterocycloalkyl;and (ii) C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;W is absent;Z is selected from the groups consisting of: (vi) aryl, substituted aryl;(vii) heteroaryl, substituted heteroaryl;(viii) —C 3 -C 12 cycloalkyl, substituted —C 3 -C 12 cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl;(ix) —C 1 -C 6 alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;(x) —C 2 -C 6 alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;or (xi) —C 2 -C 6 alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl.
  3. 5
    A compound of Formula III:as well as the pharmaceutically acceptable salts thereof, wherein: each of Y 1 , Y 2 and Y 3 are independently selected from CR 6 , N, NR 6 , S and O;A is selected from H, —(C═O)—O—R 1 , —(C═O)—R 2 , —C(═O)—NH—R 2 , or —S(O) 2 —R 1 , —S(O) 2 NHR 2 ;each R 1 is independently selected from the group consisting of: (i) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(ii) heterocycloalkyl or substituted heterocycloalkyl;(iii) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;each R 2 is independently selected from the group consisting of: (i) hydrogen;(ii) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(iii) heterocycloalkyl or substituted heterocycloalkyl;(iv) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;G is selected from —NHS(O) 2 —R 3 ;where each R 3 is independently selected from: (i) heterocycloalkyl or substituted heterocycloalkyl;and C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;W is absent;Z is selected from the groups consisting of: (vi) aryl, substituted aryl;(vii) heteroaryl, substituted heteroaryl;(viii) —C 3 -C 12 cycloalkyl, substituted —C 3 -C 12 cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl;(ix) —C 1 -C 6 alkyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;(x) —C 2 -C 6 alkenyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;—C 2 -C 6 alkynyl containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N, optionally substituted with one or more substituent selected from halogen, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;and R 6 is independently selected from: (i) hydrogen;halogen;—NO 2 ;—CN;(ii) -M-R 4 , M is O, S, NH, where R 4 is as previously defined;(iii) NR 4 R 5 , where R 4 and R 5 are as previously defined;(iv) —C 1 -C 8 alkyl, —C 2 -C 8 alkenyl, or —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;substituted —C 1 -C 8 alkyl, substituted —C 2 -C 8 alkenyl, or substituted —C 2 -C 8 alkynyl each containing 0, 1, 2, or 3 heteroatoms selected from O, S or N;—C 3 -C 12 cycloalkyl, or substituted —C 3 -C 12 cycloalkyl;—C 3 -C 12 cycloalkenyl, or substituted —C 3 -C 12 cycloalkenyl;(v) aryl;substituted aryl;heteroaryl;substituted heteroaryl;(vi) heterocycloalkyl or substituted heterocycloalkyl.
  4. 8
    A compound which is selected from compounds of Formula IV, where A, Q and G are delineated in Table 1:TABLE 1 (IV) Example # I. A II. Q G 46 47 48 49 50 51 52 —H 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 69 70 74 75 76 77 78 79 80 81 82 83 84 85 86 88 89 90 91 92 93 94 95 96 97 98 99 101 102 103 104 105 106 107 108 109 110 111
  5. 9
    Broadest claimClaim Score 89, very broad(NHIP)A compound represented by Formula IV:or a pharmaceutically acceptable salt thereof, wherein A is selected from Table 2, Q is selected from Table 3, G is selected from Table 4: TABLE 2 A-Matrix TABLE 3 Q-Matrix TABLE 4 G-Matrix